Genomic characterization of some Iranian children with idiopathic mental retardation using array comparative genomic hybridization

Farkhondeh Behjati¹, Saghar Ghasemi Firouzabadi¹, Roxana Kariminejad², Roshanak Vameghi³, Firouzeh Sajedi³, Yousef Shafaghati¹,4, Behruz Ebrahimizade Ghasemlou¹, Azadeh Shojaei³, Peyman Jamali³, Ideh Bahman¹, Hossein Najmabadi¹

¹Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, ²Kariminejad and Najmabadi Pathology and Genetics Center, ³Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, ⁴Department of Medical Genetics and Sarem Cell Research Center, Sarem Women's Hospital, ⁵Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, ⁶Shahrud Welfare Organization, Shahroud, Iran

BACKGROUND: Mental retardation (MR) has a prevalence of 1-3% and genetic causes are present in more than 50% of patients. Chromosomal abnormalities are one of the most common genetic causes of MR and are responsible for 4-28% of mental retardation. However, the smallest loss or gain of material visible by standard cytogenetic is about 4 Mb and for smaller abnormalities, molecular cytogenetic techniques such as array comparative genomic hybridization (array CGH) should be used. It has been shown that 15-25% of idiopathic MR (IMR) has submicroscopic rearrangements detectable by array CGH. In this project, the genomic abnormalities were investigated in 32 MR patients using this technique.

MATERIALS AND METHODS: Patients with IMR with dysmorphism were investigated in this study. Karyotype analysis, fragile X and metabolic tests were first carried out on the patients. The copy number variation was then assessed in a total of 32 patients with normal results for the mentioned tests using whole genome oligo array CGH. Multiple ligation probe amplification was carried out as a confirmation test.

RESULTS: In total, 19% of the patients showed genomic abnormalities. This is reduced to 12.5% once the two patients with abnormal karyotypes (upon re-evaluation) are removed.

CONCLUSION: The array CGH technique increased the detection rate of genomic imbalances in our patients by 12.5%.

It is an accurate and reliable method for the determination of genomic imbalances in patients with IMR and dysmorphism.

Key words: Array comparative genomic hybridization, chromosome abnormality, dysmorphism, genomic variation, idiopathic mental retardation

Introduction

In the general population, the incidence of mental retardation (MR) is 1-3%. The etiology of MR is very heterogeneous and it can be caused by various environmental and/or genetic factors. However, for up to 60% of cases, there is no identifiable cause. Genetic factors are the most common cause of severe MR and thought to be present in about 50% of cases.

An important genetic factor has been shown to be due to chromosome abnormalities. Microscopic and submicroscopic chromosomal rearrangements account for nearly 25% of all patients. Cryptic subtelomeric chromosomal imbalances are present in 5-20% of patients with idiopathic mental retardation (IMR). Conventional cytogenetic can only detect abnormalities larger than 4 Mbp. Use of molecular cytogenetic techniques such as fluorescent in situ hybridization (FISH) and multiple ligation probe amplification (MLPA) techniques, as targeted techniques, can detect chromosome abnormalities localized in different regions.

Address for correspondence: Dr. Farkhondeh Behjati, Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. E-mail: f_behjati@uswr.ac.ir
with smaller resolution. Array comparative genomic hybridization (array CGH) is a powerful tool for detecting very small chromosomal imbalances and is used for genome-wide screening of chromosomal imbalances in patients with IMR. Using this technique, submicroscopic abnormalities have been detected in 15-25% of patients with IMR.[11,12]

In an attempt to evaluate the chromosome abnormality rate in children with IMR and dysmorphism, 32 patients were investigated with oligonucleotide array CGH. All the patients had normal karyotype, with no fragile X or metabolic disorder.

**Materials and Methods**

**Patients**

Patients were referred to the Genetics Research Center by different clinicians. All were clinically evaluated and a clinical evaluation form was completed for each patient. Children with IMR with or without dysmorphism and without any family history of MR were recruited. The IQ test used was Raven and the patients had an IQ < 70. The age of the patients was 4-18 years. The consent form was obtained from the guardian of the patients. Both heparinized and ethylenediaminetetraacetic blood samples were obtained.

**Genetics tests**

**Karyotyping**

Cytogenetic analysis was performed on cultured peripheral blood lymphocytes stimulated with phytohaemagglutinin M, using standard techniques.[4] Karyotype was determined in all patients by high resolution by high resolution Giemsa (G)-banding technique banding.

**Metabolic tests**

Patients were screened for 30 most common metabolic disorders using tandem mass spectroscopy. The tests included phenylketonuria, galactosemia, mucopolysaccharidosis, familial tyrosinemia, primary congenital hypothyroidism, classic galactosemia, Niemann-Pick disease, carnitine palmitoyltransferase 1 and medium-chain-acyl-coa-dehydrogenase-deficiency (MCAD).

**Fragile X screening**

Genomic deoxyribonucleic acid was isolated from peripheral blood leukocytes by standard salting out method. The initial analysis of the CGG repeat region of the FMR1 gene was performed by polymerase chain reaction (PCR) amplification using the primers FR1 and FR3. Amplification products were resolved by 8% polyacrylamide gel electrophoresis. To detect and to confirm the presence of a trinucleotide expansion in males or females, Southern blot analysis was performed.

**Array CGH**

Array CGH was performed using CytoChip International Standard Cytogenetic Array 4 × 44 k (v2.0) platform provided by blue genome. The array provides whole genome coverage with probe distance of 75 kbps and resolution of 300 kb, as well as targeted enriched gene regions with increased resolution of 150-200 kbs. All hybridized slides were scanned using Inno Scan 710. 25 of the patients were repeated on the same platform against different controls for confirmation of results. Slides were analyzed using BlueFuse Multi Software, Version 3.1 (BlueGnome Ltd. Cambridge CB21 5XE UK). All the data were controlled with University of California Santa Cruz human genome browser, ensemble, decipher and database of genomic variants. Polymorphic Copy number variations (CNVs) and those not containing genes were disregarded.

**MLPA**

The kits used were SALSA P070 and P036 human subtelomere test kits (MRC-Holland, Amsterdam, Netherlands: [https://www.mrc-holland.com](https://www.mrc-holland.com)). The MLPA mix contained probes for all subtelomeric regions except the short arms of the acrocentric chromosomes (13p, 14p, 15p, 21p and 22p). MLPA analysis was carried out as suggested by the manufacturer. PCR amplification products were identified and quantified by a capillary electrophoresis using ABI 3100 genetic analyzer.

**Results**

The array CGH was performed on a total of 32 patients in whom the result of chromosome analysis, metabolic tests and fragile X screening were normal. Six patients
showed genomic abnormalities [Table 1]. The array CGH results for patients one and three are shown in Figures 1 and 2 as examples. The clinical manifestations of these patients are presented in Table 2. Two patients with normal karyotype results obtained from other centers (cases 34340, 1241) revealed large imbalances with array CGH and were consequently suspected to have chromosome abnormalities. Upon reevaluation, both patients showed chromosome rearrangements by microscope analysis [Table 1]. In both cases, mother was the carrier of a balanced reciprocal translocation.

The subtelomeric abnormalities in the patients were confirmed with MLPA test and the observed abnormality was investigated in the parents to determine its origin. Using MLPA, only in one patient (29660), the same abnormality was present in the patient’s healthy mother and it is most probably a polymorphism. For four other patients, the parents were apparently normal and therefore the genomic imbalances in the patients are most probably pathogenic. The origin of the abnormality in the last patient (32000) was not determined.

### Discussion

Many small chromosome abnormalities (less than 4 Mb) can be the causative reason for mental retardation, which cannot be detected using standard cytogenetic techniques. The reports on the chromosome abnormality rate in Iranian patients with IMR are sparse. Behjati et al.[13] reported the rate of chromosome abnormality in Iranian patients with an IMR with consanguineous parents as 1.24%. More advanced molecular Cytogenetics techniques like array CGH can be used to detect the chromosome abnormalities throughout the genome. The detection rate for chromosome abnormality has been increased using this technique. Different studies have shown an increase of 15‑25% detection rate for submicroscopic abnormalities using array CGH in patients with normal karyotypes.[14,15] In this study, 32 children with IMR (IQ<70) and dysmorphism were investigated using whole genome oligo array CGH (blue genome). The karyotype analysis, fragile X and metabolic abnormalities were normal.

| Patient code | Sex | Age (years) | Consanguinity status | Karyotype | Array CGH result | Deletion size | Duplication size | Parental result (MLPA) |
|--------------|-----|-------------|----------------------|-----------|-----------------|---------------|------------------|-----------------------|
| 34340        | M   | 3.5         | Consanguineous       | 46, XY, der (18)t (6;18) (q25.3;q21.3) mat | arr 6q26q27 (161,591,994-170,316,535) x3, 18q21.33q23 (57,854,896-76,110,994) x1 | 18.2 Mb | 8.7 Mb | N |
| 1241         | M   | 4           | Non-consanguineous   | 46, XY, der (13)t (7;13) (q32;q32) mat | arr 7q33q36.3 (136,400-158,000) x3, 13q33.3q34 (106,404,835-114,110,721) x1 | 7.7 Mb | 22 Mb | N |
| 29660        | M   | 7           | Consanguineous       | 46, XY    | arr 3p26.3p26.3 (312,929-2,001,240) x1 | 1.68 Mb | - | Mother, the same as patient |
| 30240        | M   | 8           | Consanguineous       | 46, XY    | arr 15q11.2q13.1 (21,208,406-26,193,879) x1 | 4.9 Mb | - | N |
| 34580        | F   | 5           | Consanguineous       | 46, XX    | arr 1p36.3q36.3 (769,620-2,053,075) x1 | 1.2 Mb | - | N |
| 32000        | M   | 17          | Non-consanguineous   | 46, XY    | arr 15q24.1q24.2 (70,751,053-73,322,354) x1 | 2.6 Mb | - | ND |

N: Normal, ND: Not determined, MLPA: Multiple ligation probe amplification, CGH: Comparative genomic hybridization, M: Male, F: Female

| Patient code | Dysmorphic facial features | Micrognatia | Other dysmorphic features | Hearing loss | Seizure | Autism | Unbalanced movement | Speech delay | FTT |
|--------------|---------------------------|-------------|---------------------------|--------------|---------|--------|---------------------|-------------|-----|
| 34340        | +                         | –           | Microcephaly, CHD         | +            | +       | –      | –                   | +           | +   |
| 1241         | +                         | +           | Brachycephaly, muscle atrophy | –            | –       | –      | –                   | –           | –   |
| 29660        | +                         | +           | Left hemiplegia           | –            | +       | –      | +                   | –           | –   |
| 30240        | +                         | –           | Palmar transverse crease | –            | –       | –      | –                   | –           | –   |
| 34580        | –                         | –           | Skin and eye hypopigmentation | –            | –       | –      | –                   | –           | –   |
| 32000        | –                         | –           | Macrocephaly              | –            | +       | –      | –                   | –           | –   |

FTT: Failure to thrive, CHD: Congenital heart defect, CGH: Comparative genomic hybridization
Six patients showed genomic abnormalities [Table 1]. Patients one and two both showed deletions/duplications, resulted from a maternal balanced translocation. Both patients had been reported to have normal karyotype by other laboratories. The karyotyping was repeated and showed abnormal chromosome complements confirming the array CGH results. In patient one, array CGH test showed abnormalities involving chromosomes 6 and 18. Most of the patient's clinical manifestations could be explained by partial monosomy 18q. However, partial trisomy 6q26q27 also has some specific features[16,17] which could be seen in our patient. These features include growth retardation, microcephaly, acrocephaly, hand and foot anomalies and dental decay. The partial deletion of 13q[18] and distal duplications of 7q[19] observed in-patient two are both well-known genetic disorders with a very wide spectrum of clinical phenotypes. Some of patient’s clinical manifestation such as microcephaly and genital anomaly might be attributed to partial monosomy of 13q and others such as micrognatia to partial trisomy of 7q.[20]

Patients three, four and five all had subtelomeric deletions for the short arm of chromosome 3 (3p26.3p26.3) proximal region of long arm of chromosome 15(q11.2q13.1) and short arm of chromosome 1 (1p36.33p36.33) respectively [Table 1]. The MLPA test using subtelomeric SALSA MLPA KIT P036-E1 confirmed these abnormalities. The inheritance of these abnormalities was validated for patients 35 using MLPA and only the deleted 3p were inherited from the patient’s mother. The size of 3p deletion was 1.68 Mb including CHL1 and CNTN6 genes. His healthy mother showed the same subtelomeric abnormality, which means it couldn’t be the cause of clinical manifestations and most probably is inherited as a polymorphism. However, the inherited form of 3p36.3 deletion with a size less than 1 Mb (comprising only the gene CHL1) from a normal father to two affected children has been reported by Cuoco et al.[21] The two brothers had a mild MR without any other distinct features. This group suggested the CHL1 gene was responsible for the mild phenotype symptoms observed in the patients.

The abnormality in patients four and five were apparently de novo and therefore pathogenic. Both abnormalities were consistent with previously known microdeletion syndromes. The abnormality in-patient four is consistent with Angelman syndrome compatible with the patient’s clinical manifestation[22] and patient five genomic and clinical abnormality was consistent with the known 1p36 microdeletion syndrome.

Patient six had an interstitial deletion of 15q24.1q24.2. This is a known pathogenic abnormality as the 15q24 microdeletion syndrome was first described by Sharp et al. in 2007.[23] Phenotypic features include mild to moderate developmental delay, characteristic facial features, growth retardation, hypotonia, joint laxity, digital abnormalities and genital abnormalities. Smith et al. in 2008 also described a girl (previously been assessed by FISH[24]) with autism, developmental delay and mild dysmorphism containing a 15q24 deletion overlapping

![Figure 1: Array comparative genomic hybridization result for patient 34340 showing duplication of 6q (a) and deletion of 18q (b) as: arr 6q26q27 (161,591,994-170,316,535)x3, 18q21.33q23 (57,854,896-76,110,994)x1](image1)

![Figure 2: Array comparative genomic hybridization result for patient 29660 showing deletion in 3p as: arr 3p26.3p26.3 (312,929-2,001,240)x1](image2)
the genomic region identified by Sharp et al. (Moyra Smith, personal communication), which has already been reported and is associated with intellectual disability and autism.[25]

In this study, six patients out of a total of 32 (19%) showed chromosome abnormalities using array CGH. However, two patients upon re-evaluation had gross chromosome abnormalities. Excluding these two patients, array CGH increased the chromosome abnormality detection rate by 12.5%. This is similar to some other reported cases.[15, 26-28]

**Conclusion**

The abnormality rate in patients with normal karyotype, using array CGH technique, was increased by 12.5%. The array CGH technique is an accurate and reliable method for the determination of genomic imbalances in patients with IMR and dysmorphism. However, in order to show the inheritance status of these abnormalities, FISH investigation is pending. In view of the fact that the chromosome abnormality had been missed by two laboratories, it is recommended that cytogenetic laboratories, which do not have enough expertise should refer patients with MR and dysmorphism for array CGH investigation.

**Acknowledgments**

This work is funded through a grant by the Deputy of Research of University of Social Welfare and Rehabilitation Sciences. We wish to express our gratitude to the patients and their families for their co-operation. Our sincere thanks is extended to all the clinicians for referring the patients, the personnel of Cytogenetics laboratories of Genetics and Pathology Center of Kariminejad-Najmabadi, Sarem Women's Hospital and Genetics Research Center of University of Social Welfare and Rehabilitation Sciences for their technical support.

**References**

1. Moser HG. ‘A role for gene therapy in mental retardation’ Mental retardation and Developmental Disabilities. Research Reviews, Gene Therapy. 1995;1:4-6.
2. Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, et al.
3. Behjati, et al. Array CGH in idiopathic mental retardation. Indian Journal of Human Genetics. October-December 2013 Volume 19 Issue 4 447
4. Rooney DE. Human Cytogenetics: Practical Approach. 3rd ed., Vol. 1. Oxford: Series Oxford University Press; 2001.
5. Knight SJ, Flint J. Perfect endings: A review of subtelomeric probes and their use in clinical diagnosis. J Med Genet 2000;37:401-9.
6. Flint J, Wilkie AO, Buckle VJ, Winter RM, Holland AJ, McDermid HE. The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nat Genet 1995;9:132-40.
7. Knight SJ, Regan R, Nicod A, Horsley SW, Kearney L, Homfray T, et al. Subtelomeric rearrangements in children with unexplained mental retardation. Lancet 1999;354:1676-81.
8. Flint J, Knight S. The use of telomere probes to investigate submicroscopic rearrangements associated with mental retardation. Curr Opin Genet Dev 2003;13:310-6.
9. Rooms L, Reyniers E, van Luijk R, Scheers S, Wauters J, Ceulemans B, et al. Subtelomeric deletions detected in patients with idiopathic mental retardation using multiplex ligation-dependent probe amplification (MLPA). Hum Mutat 2004;23:17-21.
10. Baroncini A, Rivieri F, Capucci A, Croci G, Franchi F, Sensi A, et al. FISH screening for subtelomeric rearrangements in 219 patients with idiopathic mental retardation and normal karyotype. Eur J Med Genet 2005;48:388-96.
11. Ropers HH. Genetics of early onset cognitive impairment. Annu Rev Genomics Hum Genet 2010;11:161-87.
12. Schooumans J, Ruivenkamp C, Holmberg E, Kylleman M, Anderlid BM, Nordenskjöld M. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). J Med Genet 2005;42:699-705.
13. Behjati F, Ghasemi Firouzabadi S, Kahrizi K, Kariminejad R, Bagherizadeh I, Ansari J, et al. Chromosome abnormality rate among Iranian patients with idiopathic mental retardation from consanguineous marriages. Arch Med Sci 2011;7:321-5.
14. Shevell M, Ashwal S, Donley D, Flint J, Gingold M, Hirtz D, et al. Practice parameter: Evaluation of the child with global developmental delay: Report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003;60:367-80.
15. Nowakowska B, Stankiewicz P, Obersztyn E, Ou Z, Li J, Chinault AC, et al. Application of metaphase HR-CGH and targeted chromosomal microarray analyses to genomic characterization of 116 patients with mental retardation and dysmorphic features. Am J Med Genet A 2008;146A: 2361-9.
16. Goh DL, Tan AS, Chen JY, Van Den Bergh JA. Dysmorphic sibs trisomic for the region 6q22.1 – 6q23.3. J Med Genet 2000;37:889-92.
17. Pirvnick EK, Qumsiyeh MB, Tharapel AT, Summitt JB, Wilroy RS. Partial duplication of the long arm of chromosome 6: A clinically recognisable syndrome. J Med Genet 1990;27:523-6.
18. Walczak-Sztulpa J, Wisniewska M, Latos-Bielenska A, Linné M, Kelbova C, Bellitz B, et al. Chromosome deletions in 13q33-34: Report of four patients and review of the literature. Am J Med Genet A 2008;146:337-42.
19. Alfonsi M, Palka C, Morizio E, Gatta V, Franchi S, Guanciali Franchi P, et al. A new case of pure partial 7q duplication. Cytogenet Genome Res 2012;136:1-5.
20. Shojaei A, Behjati F, Derakhshandeh-Peykar P, Razzaghy-Azar M, Otukesh H, Kariminejad R, et al. Partial trisomy 7q and monosomy 13q in a child with disorder of sex development: Phenotypic and genotypic findings. Gene 2013;517:137-45.
21. Cuoco C, Ronchetto P, Gimelli S, Béna F, Divizia MT, Lerone M, et al. Microarray based analysis of an inherited terminal 3p26.3 deletion, containing only the CHL1 gene, from a normal father to his two affected children. Orphanet J Rare Dis 2011;6:12.
22. Ebrahimizadeh B, Shafeghati Y, Almadani N, Vameghi R, Sajedi F, Firouzabadi SG, et al. Genetic investigation in a patient with angelman syndrome using MLPA and array CGH technique. Genetics in the 3rd Millennium 2012;10:2684-9.
23. Sharp AJ, Selzer RR, Veltman JA, Gimelli S, Gimelli G, Striano P, et al. Characterization of a recurrent 15q24 microdeletion syndrome. Hum Mol Genet 2007;16:567-72.
24. Smith M, Filipek PA, Wu C, Bocian M, Hakim S, Modahl C, Spence MA. Analysis of a 1-megabase deletion in 15q22-q23 in an autistic patient: Identification of candidate genes for autism and of homologous DNA segments in 15q22-q23 and 15q11-q13. Am J Med Genet, 2000; 96:765-70.
25. McInnes LA, Nakamine A, Pilorge M, Brandt T, Jiménez González P, Fallas M, et al. A large-scale survey of the novel 15q24 microdeletion syndrome in autism spectrum disorders identifies an atypical deletion that narrows the critical region. Molecular Autism. 2010;1:5.
26. Wagenstaller J, Spranger S, Lorenz D, Kazmierczak B, Nathrath M, Wahl D, et al. Copy-number variations measured by single-nucleotide-polymorphism oligonucleotide arrays in patients with mental retardation. Am J Hum Genet. 2007; 81:768-79.
27. Fan YS, Jayakar P, Zhu H, Barbouth D, Sacharow S, Morales A, et al. Detection of pathogenic gene copy number variations in patients with mental retardation by genomewide oligonucleotide array comparative genomic hybridization. Hum Mutat. 2007;28:1124-32.
28. Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, Otto PA, et al. Array-CGH detection of microrearrangements in mentally retarded individuals: Clinical significance of imbalances present both in affected children and normal parents. J Med Genet. 2006;43:180-6.

Cite this article as: Behjati F, Firouzabadi SG, Kariminejad R, Vameghi R, Sajedi F, Shafaghati Y, et al. Genomic characterization of some Iranian children with idiopathic mental retardation using array comparative genomic hybridization. Indian J Hum Genet 2013;19:443-8.

Source of Support: This work is funded through a grant by the deputy of research of University of Social Welfare and Rehabilitation Sciences. Conflict of Interest: None declared.